Your shopping cart is currently empty

PLK4-IN-7 is a selective and orally active PLK4 inhibitor with an IC50 of 7.9 nM. It demonstrates potent antitumor activity and exhibits good metabolic stability. PLK4-IN-7 can be applied to research in tumors such as neuroblastoma.
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | PLK4-IN-7 is a selective and orally active PLK4 inhibitor with an IC50 of 7.9 nM. It demonstrates potent antitumor activity and exhibits good metabolic stability. PLK4-IN-7 can be applied to research in tumors such as neuroblastoma. |
| Targets&IC50 | PLK4:7.9 nM |
| In vitro | PLK4-IN-7 (Compound 25) (5 days) effectively inhibits the viability of CHP-134 neuroblastoma cells, with an EC50 of 88 nM. |
| In vivo | PLK4-IN-7, administered orally at doses of 30-100 mg/kg twice daily for 16 consecutive days, exhibits significant tumor growth inhibition in a CHP-134 neuroblastoma xenograft mouse model. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.